CTOs on the Move

NxStage Medical

www.nxstage.com

 
NxStage System One dialysis machines offer the comfort and flexibility of hemodialysis at home. Discover how our products can improve your quality of life.
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million
  • www.nxstage.com
  • 350, Merrimack Street
    Lawrence, MA USA 01843
  • Phone: 978.687.4700

Executives

Name Title Contact Details

Similar Companies

Pipeline Therapeutics

Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair. The company`s lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor (GSI) to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy. The company also has a portfolio of programs, including PIPE-307, focused on remyelination and axonal repair, to address a range of neurological disorders, including multiple sclerosis.

ALDA Pharmaceuticals

ALDA Pharmaceuticals Corp. is a Richmond, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Forest Labs

Forest Labs is a Jersey City, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Crucell Biologics

Crucell N.V. (Crucell) is a biopharmaceutical company. The Company is focused on developing, producing and marketing products that combat infectious diseases. Crucell product candidates include flu-mAb, an antibody product effective against a range of

Ripple Therapeutics

The Ripple Therapeutics Epidel® technology is founded on a discovery that drugs can be engineered into controlled release materials without the use of polymers or excipients. The proprietary prodrugs are new chemical entities (NCEs) that have unique properties that allow them to be processed into standalone drug delivery implants (e.g. intravitreal implants, micro/nanoparticles, etc.) or as coatings on medical devices. Ripple Therapeutics implants and coatings are made up entirely from the prodrug without a polymeric carrier to control the implant or drug release properties. The implants and coatings undergo surface erosion to give zero order drug release profiles and are highly engineerable (e.g. different forms, shapes, and sizes) to tailor drug dose and duration for the specific indication of interest. The flexibility in molecular design results in drug doses that are within the therapeutic window, delivering the right amount of drug for the right amount of time. This has the potential to improve patient safety and clinical outcomes.